Lasofoxifene is the first selective estrogen receptor modulator (SERM) to help vaginal atrophy, says a multicenter trial presented at the 15th Annual Meeting of the North American Menopause Society (NAMS). Investigators found the drug reduced dryness with few side effects.
Lasofoxifene is the first selective estrogen receptor modulator (SERM) to help vaginal atrophy, says a multicenter trial presented at the 15th Annual Meeting of the North American Menopause Society (NAMS). Investigators found the drug reduced dryness with few side effects.
Nearly 400 postmenopausal women aged 46 to 82, all of whom had some degree of vaginal discomfort, were enrolled in the placebo-controlled, double-blind study at 31 sites. Three daily doses of lasofoxifene were tested: 0.025 mg, 0.25 mg, and 0.5 mg. Vaginal atrophy was assessed via questionnaire at baseline and treatment weeks 8, 12, and 24.
By 12 weeks, all three dosages significantly improved vaginal dryness/soreness compared to placebo (63%, 65%, and 62%, respectively, vs. 35%; P<0.001). A similar but less dramatic difference was seen for burning/itching (38%, 43%, and 36%, respectively, vs. 22%; P≤0.074). The drug also reduced symptoms associated with sexual intercourse.
Bachmann G, Gawss M, Moffett A, et al. Lasofoxifene improves patients' symptoms associated with vaginal atrophy. P-63. Presented at the 15th Annual Meeting of the North American Menopause Society in Washington, D.C.
Unraveling preeclampsia: Insights into heterogeneity and intravascular inflammation
April 22nd 2024A recent study delved into the intricate clusters of term preeclampsia, shedding light on its diverse manifestations and the pivotal role of intravascular inflammation, paving the way for improved classification and management strategies.
Read More
Personalized opioid protocol for cesarean deliveries: Reduced prescriptions reported
April 19th 2024A recent suggests that implementing a personalized opioid prescription protocol significantly reduces total morphine milligram equivalents and the number of opioid tablets prescribed at discharge following cesarean delivery.
Read More
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More